Biological Activity
HMG-CoA reductase inhibitor; decreases levels of low density lipoprotein. Has multiple biological effects including bone formation stimulation, inhibition of smooth muscle cell proliferation and migration, induction of ferroptosis, and anticancer and anti-inflammatory activity. Inactive lactone prodrug of simvastatin hydroxy acid, naturally bioactivated in vivo following oral administration.
Compound Libraries
Simvastatin is also offered as part of the Tocriscreen Plus and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 418.57 |
| Formula | C25H38O5 |
| Storage | Desiccate at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 79902-63-9 |
| PubChem ID | 54454 |
| InChI Key | RYMZZMVNJRMUDD-HGQWONQESA-N |
| Smiles | [H][C@@]12C(C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(O3)=O)=C[C@H](C)C[C@@H]1OC(C(C)(C)CC)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.93 | 50 | |
| ethanol | 31.39 | 75 |
Preparing Stock Solutions
The following data is based on the product molecular weight 418.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.39 mL | 11.95 mL | 23.89 mL |
| 5 mM | 0.48 mL | 2.39 mL | 4.78 mL |
| 10 mM | 0.24 mL | 1.19 mL | 2.39 mL |
| 50 mM | 0.05 mL | 0.24 mL | 0.48 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Garrett et al (2001) Statins and bone formation. Curr.Pharm.Des. 7 715 PMID: 11405194
Kaushal et al (2003) Potential anticancer effects of statins: fact or fiction? Endothelium 10 49 PMID: 12699077
White (1999) Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J.Clin.Pharmacol. 39 111 PMID: 11563401
Reinoso et al (2002) Preclinical pharmacokinetics of statins. Methods Find.Exp.Clin.Pharmacol. 24 593 PMID: 12616706
Keywords: Simvastatin, supplier, HMG-CoA, reductase, inhibitors, inhibits, Reductases, ferroptosis, hyperlipidemia, hypolipemic, HMG-CoA, Reductase, Ferroptosis, HMG-CoA, Reductase, Tocris Bioscience
